Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prabhavathi Fernandes

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Antimicrobial Agents and Chemotherapy|October 26, 2018
Erratum for Piccinelli et al., "<i>In Vitro</i> Activity of Solithromycin against Erythromycin-Resistant Streptococcus agalactiae"Giorgio Piccinelli, Prabhavathi Fernandes, Carlo Bonfanti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 7, 2011
Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjectsJ Gordon Still, Kay Clark, Thorsten P Degenhardt, et al.
Antimicrobial Agents and Chemotherapy|November 16, 2011
In vitro and in vivo activity of solithromycin (CEM-101) against Plasmodium speciesSergio Wittlin, Eric Ekland, J Carl Craft, et al.
Antimicrobial Agents and Chemotherapy|June 12, 2019
Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection ModelOlanrewaju O Okusanya, Alan Forrest, Sujata M Bhavnani, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 2016
Solithromycin, a novel macrolide, does not prolong cardiac repolarization: a randomized, three-way crossover study in healthy subjectsBorje Darpo, Philip T Sager, Prabhavathi Fernandes, et al.
Antimicrobial Agents and Chemotherapy|February 2, 2011
Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjectsJ Gordon Still, Jennifer Schranz, Thorsten P Degenhardt, et al.
Antimicrobial Agents and Chemotherapy|September 22, 2010
Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesisBeatriz Llano-Sotelo, Jack Dunkle, Dorota Klepacki, et al.
Antimicrobial Agents and Chemotherapy|March 20, 2013
Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumoniaDavid Oldach, Kay Clark, Jennifer Schranz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2015
A Phase 2 Trial of Oral Solithromycin 1200 mg or 1000 mg as Single-Dose Oral Therapy for Uncomplicated GonorrheaEdward W Hook, Matthew Golden, Brian D Jamieson, et al.
Pharmaceutical Research|February 9, 2019
Analyzing the Mechanisms Behind Macrolide Antibiotic-Induced Liver Injury Using Quantitative Systems Toxicology ModelingJeffrey L Woodhead, Kyunghee Yang, David Oldach, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Antimicrobial Agents and Chemotherapy|October 26, 2018
Erratum for Piccinelli et al., "<i>In Vitro</i> Activity of Solithromycin against Erythromycin-Resistant Streptococcus agalactiae"Giorgio Piccinelli, Prabhavathi Fernandes, Carlo Bonfanti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 7, 2011
Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjectsJ Gordon Still, Kay Clark, Thorsten P Degenhardt, et al.
Antimicrobial Agents and Chemotherapy|November 16, 2011
In vitro and in vivo activity of solithromycin (CEM-101) against Plasmodium speciesSergio Wittlin, Eric Ekland, J Carl Craft, et al.
Antimicrobial Agents and Chemotherapy|June 12, 2019
Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection ModelOlanrewaju O Okusanya, Alan Forrest, Sujata M Bhavnani, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 2016
Solithromycin, a novel macrolide, does not prolong cardiac repolarization: a randomized, three-way crossover study in healthy subjectsBorje Darpo, Philip T Sager, Prabhavathi Fernandes, et al.
Antimicrobial Agents and Chemotherapy|February 2, 2011
Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjectsJ Gordon Still, Jennifer Schranz, Thorsten P Degenhardt, et al.
Antimicrobial Agents and Chemotherapy|September 22, 2010
Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesisBeatriz Llano-Sotelo, Jack Dunkle, Dorota Klepacki, et al.
Antimicrobial Agents and Chemotherapy|March 20, 2013
Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumoniaDavid Oldach, Kay Clark, Jennifer Schranz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2015
A Phase 2 Trial of Oral Solithromycin 1200 mg or 1000 mg as Single-Dose Oral Therapy for Uncomplicated GonorrheaEdward W Hook, Matthew Golden, Brian D Jamieson, et al.
Pharmaceutical Research|February 9, 2019
Analyzing the Mechanisms Behind Macrolide Antibiotic-Induced Liver Injury Using Quantitative Systems Toxicology ModelingJeffrey L Woodhead, Kyunghee Yang, David Oldach, et al.
Pageof 6